Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 77926996Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award categories
- Internal Medicine
NIH Funding · FY2025
Linked Award Amount
$1.1M
Full award amounts, FY2025
Award Records
2
Records listing this PI
Award-Linked Rank
#14,531
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2025 award records by amount
NIH award records listing Remi Adelaiye-ogala as a PI. Multi-PI records show the full award amount for context.
- 5R01CA290402-02R01Posttranslational modifications of glucocorticoid receptor associated with drug-resistance in prostate cancer$588.4Kaward amount
- 5R37CA272726-03R37Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers$541.2Kaward amount
Award organization
Organizations that administered FY2025 awards listing Remi Adelaiye-ogala as a PI.
FY2025 award administered by University at Buffalo (NY).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardUniversity at Buffalo
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2025$2M Cumulative Funding
- 2025R01 Grant Holder
- 2026Entered Top 50% NationallyRanked #8093